🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

TIL-Driven De-escalated Chemotherapy in Stage I-II TNBC

RecruitingPhase 2Ages 18 Years - anyAllD'Or Institute for Research and Education
NCT07074106 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This is a phase II clinical study testing a more personalized and lighter chemotherapy approach for women with stage I or II triple-negative breast cancer. The treatment is adjusted based on signs from the immune system (called tumor-infiltrating lymphocytes, or TILs) and imaging results during treatment. Patients with stage I triple-negative breast cancer (regardless of TIL levels) and those with stage II disease and high TILs (50% or more) will receive a combination of two chemotherapy drugs (carboplatin and a taxane) for four cycles. If imaging shows the tumor has completely disappeared after this treatment, the patient will go straight to surgery. If the tumor is still visible, the treatment will be strengthened with additional chemotherapy drugs (anthracycline and cyclophosphamide), with or without a medicine called pembrolizumab, which helps the immune system fight cancer. The m

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Histologically confirmed primary invasive breast carcinoma. * One of the following conditions: * Clinical stage T1c N0 M0 with any level of TILs; or * Clinical stage T2 N0 M0 with TILs ≥ 50%. * Estrogen receptor (ER) and progesterone receptor (PR) expression \< 10%. * HER2-negative or non-amplified, according to current ASCO-CAP criteria. * No evidence of distant metastasis based on imaging performed prior to study entry (chest/abdomen/pelvis CT scan or FDG PET-CT). * Age ≥ 18 years. * ECOG performance status of 0 to 2. * Adequate organ function Exclusion Criteria: * The subject has an uncontrolled severe concomitant condition, including but not limited to: active or ongoing infection, unstable angina, uncontrolled cardiac arrhythmia, congestive heart failure (NYHA Class III or IV), active ischemic heart disease, or chronic liver or kidney disease. * Pregnant or breastfeeding participants. * History of severe allergic reactions, including anaphylaxis or other hypersensitivity reactions to platinum-based agents or taxanes.
💊

What it tests

  • Carboplatin and a Taxane
📍

Where

5 sites
Instituto D'Or de Pesquisa e Ensino de Brasília
Brasília, Brazil
Instituto D'Or de Pesquisa e Ensino de Curitiba
Curitiba, Brazil
Instituto D'Or de Pesquisa e Ensino do Rio de Janeiro
Rio de Janeiro, Brazil
Instituto D'Or de Pesquisa e Ensino de Salvador
Salvador, Brazil
Instituto D'Or de Pesquisa e Ensino de São Paulo
São Paulo, Brazil
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy